Bladder cancer

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 207-212

  Özen, Haluk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FIBRIN DEGRADATION PRODUCT; GEMCITABINE; METHOTREXATE; NUCLEAR PROTEIN; TELOMERASE; TUMOR ANTIGEN; VINBLASTINE;

BLADDER CANCER; CANCER INVASION; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC TEST; ENZYME ACTIVITY; HEMATURIA; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; HUMANS; NEOPLASM STAGING; PROBABILITY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0032892452     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00013     Document Type: Review

References (23)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997, CA Cancer J Clin 1997, 47:5-27.
2. Lee D-H, Yang S-C, Hong S-J, Chung B-H, Kim IY: Telomerase: A potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998, 4:535-538. Telomerase is an enzyme that immortalizes cells by maintaining a constant telomere length. Telomerase activity was detected by the PCR method in 95.7% of the bladder wash samples in patients with TCC. This high sensitivity was also observed in patients with low-stage disease in whom cytology was not very helpful.
3. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC-S: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998, 82:708-714. Telomerase activity was tested in voided urine samples of patients with TCC or various urological anomalies, and from a normal, healthy population. Telomerase activity was present in 82% of grade 1 and 2 TCC, while standard cytology was positive in only 31%. However, in patients with urological disorders there was a disturbing 34% false-positive result rate. Telomerase activity seemed to be a very sensitive tumor marker especially in low-grade tumors, where we are seriously in need of a new marker.
4. Muller M, Krause H, Heicappoll R, Tischendorf J, Shay JW, Miller K:Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998, 4:1949-1954.
5. Murphy WM, Rivera-Ramirez I, Medina CA, Wright NJ, Wajsman Z: The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 1997, 158:2102-2106.
6. Schamhart DHJ, de Reijke TM, van der Poel HG, Witjes JA, de Boer EC, Kurth K-H, Schalken JA: The Bard BTA test: Its mode of action, sensitivity, specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. Eur Urol 1998, 34:99-106.
7. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL, and the Multicenter Study Group: Clinical evaluation of the BTA Trak assay and comparison to voided urine cytology and BTA test in patients with recurrent bladder tumors. Urology 1997, 50:882-887.
8. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al.: Use of a new tumor marker, urinary NMP-22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996, 156:363-367.
9. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al.: Evaluation of NMP-22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998, 159:394-398. This is a multicenter study performed to evaluate the sensitivity of NMP-22 in the diagnosis of TCC in 231 patients with a history of bladder cancer. The optimal reference value for detection of TCC was determined as 6.4 U/ml. Overall sensitivity and specificity for NMP-22 was 68% and 80%, respectively. NMP-22 was found to be superior to cytology.
10. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC-S: Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human bladder cancer. Urology 1998, 52:398-402.
11. Wiener HG, Mian CH, Haitel A, Pycha A, Scharzl G, Marberger M: Can urine bound tests replace cystoscopy in the management of bladder cancer? J Urol 1998, 159:1876-1880.
12. Johnston B, Morales A, Emerson L, Lundie M: rapid detection of bladder cancer: A comparative study of point of care tests. J Urol 1997, 158:2098-2101.
13. Soloway MS: T1 and T2 bladder cancer: Selecting optimal therapy. Eur Urol 1998, 33(suppl):16-17.
14. Hermann GG, Horn T, Steven K: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder carinoma. J Urol 1998, 159:91-94. The patients with T1 disease were reclassified as T1a, T1b, and T1c according to the depth of invasion in the submucosa. The survival of patients who were treated by transurethral resection only was found to be influenced only by the depth of invasion of the submucosa and p53 status. Patients with the deepest tumor invasion (T1c) associated with p53 positivity need aggressive treatment to prevent ominous course of the disease.
15. Witjes JA, Van Der Meijden APM, Collette L, Sylvester R, Debruyne FMJ, Van Aubel A, Witjes WPJ, and the EORTC GU Group and the Dutch South East Cooperative Urological Group: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and Mitomycin C in superficial bladder cancer. Urology 1998, 52:403-410.
16. Tuncer S, Tekin MI, Ozen H, Bilen C, Unal S, Remzi D: Detection of Bacillus Calmette-Guerin in the blood by the polymerase chain reaction method of treated bladder cancer patients. J Urol 1997, 158:2109-2112.
17. Hautmann RE, Paiss T: Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy. J Urol 1998, 159:1845-1850. This study clearly shows that continent diversions improve survival significantly by decreasing the time period from diagnosis of invasive disease to radical cystectomy. Patients and physicians seemed to overcome their reluctance to pursue radical cystectomy when there is an option of continent diversion.
18. Iselin CE, Robertson CN, Webster GD, Vieweg J, Paulson DF: Does prostatic transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder carcinoma. J Urol 1997, 158:2123-2126.
19. Lebret T, Herve J-M, Barre P, Gaudez F, Lugagne P-M, Barbagelatta M, Botto H: Urethral recurrence of transitional cell carcinoma of the bladder. Eur Urol 1998, 33:170-174.
20. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, et al.:Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997, 80:1966-1972.
21. Redman BG, Smith DC, Flaherty L, Du W, Hussain M: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urethelial carcinoma. J Clin Oncol 1998, 16:1844-1848.
22. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urethelial cancer. J Clin Oncol 1997, 15:3441-3445.
23. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urethelial cancer. J Clin Oncol 1997, 15:3394-3398.